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Obesity is an established risk factor for stroke and has reached epidemic proportions. 
However, its impact on intravenous thrombolysis (IVT) applied for acute ischemic 
stroke is not well known. We aimed to compare the clinical outcome and safety after 
IVT in obese (body mass index (BMI) ≥30 kg/m2) and non-obese (BMI <30 kg/m2)  
patients with ischemic stroke. 
 
Methods  
Data of 304 consecutive stroke patients (251 non-obese and 53 obese) treated with 
IVT were studied. We assessed the rate of favorable outcome (modified Rankin Scale 
score 0 or 1), mortality and symptomatic intracranial hemorrhage (sICH) in the two 
groups. 
 
Results 
Obese patients presented more often with diabetes mellitus (30.2% vs. 12.4%, p<0.01) 
and arterial hypertension (77.4% vs. 61.4%, p=0.03) as compared with their non-obese 
counterparts. At three months, the rate of favorable outcome was lower in obese 
compared to non-obese patients (50.9% vs. 68.1%, p=0.02). More obese than non-
obese patients died (13.2% vs. 4.0%, p=0.01), while the rate of sICH was similar in the 
two groups (1.9% vs. 1.6%, p=1.0). After multivariable adjustment, obesity still 
remained an independent predictor of unfavorable outcome (p=0.04) and mortality 
(p=0.04). 
 
Conclusion 
Our data indicate that obesity is an independent predictor of unfavorable clinical 
outcome and mortality in acute ischemic stroke treated with IVT.  
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Obesity is an established vascular risk factor with increasing prevalence and huge 
impact on public health worldwide.1 It has been shown to be an independent predictor 
for ischemic stroke with an 4% risk increase for each unit augmentation in body mass 
index (BMI).2 Thus, obese patients will constitute an increasing subgroup of candidates 
for intravenous thrombolysis (IVT). However, little is known about the impact of obesity 
on outcome in stroke patients treated with IVT. Therefore, we aimed to assess the 
clinical outcome and safety in obese and non-obese patients undergoing IVT for acute 
ischemic stroke.   
 
METHODS 
We studied prospectively collected data of consecutive patients with acute ischemic 
stroke who underwent IVT with alteplase, but no other or additional thrombolytic 
treatment at the University Hospital of Zurich between January 1, 2005, and November 
30, 2008. Routine baseline investigations and definition of variables have been 
reported in a previous study.3 Body mass index was calculated as weight in kilograms 
divided by height squared in meters. Body weight and height were either obtained from 
the patient or the accompanying relatives at admission, or measured by nurse during 
hospital stay. Patients were classified as obese when BMI was 30 kg/m2 or more. 
Intravenous thrombolysis was performed according to current guidelines except the use 
of extended time window up to 4.5 hours, the latter based on a pooled analysis 
presented at the 27th International Stroke Conference in February 2002 (San Antonio, 
Texas).4,5 Patients and relatives were informed about the off-label use of alteplase 
beyond the 3-hour time window and informed consent was obtained prior to IVT. All 
patients were monitored in our stroke unit for at least 24 hours after thrombolysis. The 
study is approved by the local ethics committee.  
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Symptomatic intracranial hemorrhage (sICH) was defined as neurological deterioration 
causing a ≥4 points worsening on the NIHSS causally related to ICH detected by CCT 
within 36 hours after initiation of IVT. Asymptomatic intracranial hemorrhage was 
defined as any ICH without neurological deterioration. Clinical outcomes were mortality 
and the modified Rankin Scale (mRS) score at 3 months, the latter dichotomized into 
favorable (0-1) and unfavorable (2-6).  
 
Statistical analysis 
Statistical analysis was performed with SPSS 10.0 for MacIntosh statistical software 
(SPSS Inc). Statistical significance for intergroup differences was assessed by the 2 
or Fisher’s exact test (the latter if some expected counts in the two-by-two table were 
too low) for categorical variables and the Mann-Whitney U test for continuous variables. 
Backward stepwise logistic regression analyses were performed to assess an 
independent association between obesity and the predefined endpoints. The variables 
included were age, gender, hypertension, diabetes mellitus, smoking status, baseline 
NIHSS score, time from stroke onset to treatment and pre-stroke treatment with 
antiplatelet agents. Significance was declared at 2-sided p<0.05 level. 
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A total of 304 patients were eligible for this study; 53 (17%) of them were obese (mean 
BMI 33.2 kg/m2) and 251 (83%) non-obese (mean BMI 25.1 kg/m2). Obese patients 
presented more often with arterial hypertension and diabetes mellitus as compared with 
their non-obese counterparts, whereas age, stroke severity, time to treatment and other 
baseline characteristics were similar in both cohorts (Table). At three months, 27 of 53 
(50.9%) obese and 171 of 251 (68.1%) non-obese patients experienced a favorable 
outcome (p=0.02), while seven of 53 obese (13.2%) and 10 of 251 (4.0%) non-obese 
patients died (p=0.01) (Figure). Symptomatic ICH occurred in one of 53 (1.9%) obese 
and 4 of 251 (1.6%) non-obese patients (p=1.0), while asymptomatic ICH was 
observed in 7 of 53 (13.2%) obese and 35 of 251 (13.9%) non-obese patients (p=0.62). 
Logistic regression analyses identified a higher baseline NIHSS score (p<0.01) and 
obesity (p=0.04) as independent predictors of unfavorable clinical outcome, whereas 
baseline NIHSS score (p<0.01), age (p=0.01), time to treatment (p=0.02) and obesity 
(p=0.04) predicted mortality independently. 
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Our study suggests an adverse influence of obesity on IVT in ischemic stroke. Obese 
patients had less often a favorable outcome and were at higher mortality risk as 
compared with their non-obese counterparts. Logistic regression analyses suggest that 
the poor outcome in the obese cohort is independent from the associated vascular risk 
factors such as hypertension or diabetes mellitus. 
Several reasons might explain the unfavorable clinical outcome in obese stroke 
patients treated with IVT. First, obesity has been shown to be associated with a 
proinflammatory and prothrombotic state,6,7 thus potentially hampering the clot 
dissolving effect of alteplase. Plasminogen activator inhibitor-1 is a main inhibitor of 
fibrinolysis and seems to be consistently overexpressed in adipose tissue.8 
Furthermore, obesity is closely associated with the metabolic syndrome (MetS),9 and 
the rate of MCA recanalization is lower in patients as compared to those without 
MetS.10 Second, body weight was above 100 kg in 13 (25%) of obese patients; thus, 
the dose of alteplase might have been insufficient in these patients as the maximum 
dose is limited at 90 mg. In line with this, increased body weight in patients with acute 
myocardial infarction was associated with lower probability of coronary artery 
recanalization after IVT.11 As pretreatment status of cerebral arteries and recanalization 
were unknown in our study, however, we have no means to support this hypothesis. 
Third, obese patients might be prone to more in-hospital complications such as venous 
thromboembolism.12 In our study, obesity was associated with a higher mortality. This 
finding is in line with a previous study that reported a greater risk of all-cause and 
cardiovascular death among stroke patients with higher BMI.13 The sICH risk in the 
obese cohort was similar compared to the non-obese patients. However, the low 
number of sICH precludes any definite conclusions on hemorrhage risk of IVT in obese 
stroke patients.  
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  This study has some limitations. The cohort size of obese patients is small and 
does not allow to generalize our findings. Thus, our observation should be interpreted 
with caution and needs to be confirmed by further studies. Metabolic syndrome and 
hyperglycemia, both associated with obesity and higher resistance to IVT,10,14 might 
have contributed to the effect of obesity. Another limitation of this study is that body 
weight and height were self-reported by patients or caregivers in part, although the 
validity of self reported measurements of body weight has been shown.15 Finally, the 
outcomes were measured in clinical routine and thus were not necessarily obtained by 
blinded assessors. 
In conclusion, our study suggests that obesity is an independent predictor of 
unfavorable clinical outcome and mortality in stroke patients treated with IVT. This 
observation might have a practical consequence as obesity may indicate a subgroup of 
patients with poor response to IVT, who may benefit from more aggressive treatment 
and monitoring strategies.  
 
 
 
 
 
 Table. Baseline Characteristics in Patients with BMI ≥ 30 kg/m2 vs. BMI < 30 kg/m2 
 
  BMI ≥ 30 kg/m2 
(n=53) 
BMI < 30 kg/m2 
(n=251) P Value 
Mean age ± SD [years] 63.6 ± 13.6 63.6 ± 14.7 0.99 
Male sex 62.3 (33) 66.1 (166) 0.63 
Hypertension 77.4 (41) 61.4 (154) 0.03 
Diabetes mellitus 30.2 (16) 12.4 (31) <0.01 
Coronary artery disease 15.1 (8) 17.1 (43) 0.84 
Current smoking 28.3 (15) 26.7 (67) 0.87 
Total Cholesterol ± SD [mmol/L] 5.2 ± 1.2 5.1 ± 1.2 0.52 
Prestroke antiplatelet treatment 35.8 (19) 32.3 (81) 0.63 
Admission systolic blood pressure ± SD [mmHg] 154.6 ± 23.1 154.1 ± 26.4 0.90 
Admission diastolic blood pressure ± SD [mmHg] 87.8 ± 13.9 88.9 ± 14.2 0.66 
Admission blood glucose ± SD [mmol/L] 7.2 ± 2.6 6.6 ± 2.3 0.12 
Baseline NIHSS score ± SD 10.7 ± 5.9 10.0 ± 5.5 0.37 
Stroke onset to treatment time ± SD [min] 161.3 ± 38.6  158.4 ± 43.0 0.65 
Stroke subtype (TOAST-classification)  
     Cardioembolism 49.1 (26) 53.0 (133) 
     Large-artery atherosclerosis 17.0 (9) 6.4 (16) 
     Small-vessel disease 9.4 (5) 6.4 (16) 
     Other determined etiology 3.8 (2) 5.2 (13) 
     Undetermined etiology 20.7 (11) 29.0 (73) 
0.09 
Values are % (n) unless noted otherwise. 
SD standard deviation, NIHSS National Institutes of Health Stroke Scale
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